

Disclosures

ASRS adheres to the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The Planning Committee members below have responded that they have no relevant financial relationships with ineligible entities:

Planning Committee Members:

Ferhina Ali, MD, MPH

Andre Witkin, MD

Robin Vora, MD

Henry Leder MD

The Planning Committee members below have disclosed the following financial relationships with ineligible entities:

Planning Committee Members: Name of Ineligible Company/Nature of Relationship

J. Fernando Arevalo, MD, PhD, FACS, FASRS: Abbvie/Consultant Relationship; Genentech/Consultant Relationship; Springer SBM LLC/Royalties or Patent Beneficiary relationship; Topcon Medical/Grant support relationship; Elsevier/Royalties or Patent Beneficiary relationship; Thea Laboratories/Consultant Relationship; DORC/Consultant Relationship; EyePoint Pharma/Consultant Relationship; Alimera/Consultant Relationship

Caroline Baumal, MD: Genentech/Consultant Relationship; Regeneron/Speaker Bureau relationship; Zeiss/Speaker Bureau relationship; Alcon/Consultant relationship; Apellis/Speaker Bureau relationship; Novartis/Consultant relationship; Ora/Consultant relationship

Netan Choudhry, MD, FRCS(C), FASRS: Genentech/Consultant relationship; Regeneron/Speaker Bureau relationship; Zeiss/Speaker Bureau relationship; Alcon/Consultant relationship; Novartis/Consultant relationship; Ora/Consultant relationship

Roger Goldberg, MD, MBA: Apellis/Investigator relationship/Consultant relationship/payments to institution; Genentech (Roche)/ Consultant relationship/Principal Investigator relationship/Speaker Bureau relationship; Regeneron/Advisory Board Member relationship; Zeiss/Consultant relationship/Payment to Institution relationship; Boehringer Ingelheim/Payment to Institution relationship; Novo Nordisk/ Principal

Investigator relationship; Coherus Biosciences/Advisory Board Member; Biogen/Speaker Bureau relationship; Affamed/Principal Investigator relationship; Outlook Therapy/Advisory Board Member relationship; EyePoint/Advisory Board Member relationship; Annexon/Principal Investigator relationship; Neurotech/Principal Investigator relationship

Nieraj Jain, MD: Verana Health/Consultant relationship

Peter Kaiser, MD, FASRS: Revopsis/Consultant relationship; Bayer/Consultant relationship; Regeneron/Consultant relationship; Ocular Therapeutics/Consultant relationship; Allergo/Consultant relationship; Allergan/Consultant relationship; Bausch and Lomb/Consultant relationship; Regenex Bio/Consultant relationship; Nanoscope Therapeutics/Consultant relationship; Ray Therapeutics/Consultant relationship; Affamed/Consultant relationship; Novartis/Consultant relationship; Stealth Biotherapeutics/Consultant relationship

Eric Schneider, MD: Carl Zeiss Meditec/Consultant relationship/Principal Investigator relationship; Notal Vision/Principal Investigator/Consultant relationship; Oxurion/Principal Investigator relationship; AffaMed Therapeutics/Principal Investigator relationship; OcuTerra Therapeutics/Principal Investigator relationship; Regeneron Pharmaceuticals/Principal Investigator relationship

Lejla Vajzovic, MD, FASRS: AGTC/Principal Investigator relationship

Yoshihiro Yonekawa, MD, FASRS: Alcon/Consultant relationship; Pykus/Consultant relationship; Tarsus/Consultant relationship; Versant Health/Advisory Board member relationship; Bausch Health/Consultant relationship; Regeneron/Consultant relationship